Nuvectis Pharma (NVCT) Cash from Financing Activities (2021 - 2026)
Nuvectis Pharma (NVCT) posted Cash from Financing Activities of $7000.0 for Q1 2026, down 95.78% sequentially from $166000.0 in Q4 2025, and down 99.95% YoY from $15.5 million in Q1 2025.
Nuvectis Pharma (NVCT) Cash from Financing Activities (2021 - 2026) Analysis & Trends
Nuvectis Pharma has reported Cash from Financing Activities for 6 years, with the latest figure at $7000.0 in Q1 2026.
- Quarterly Cash from Financing Activities fell 99.95% year-over-year to $7000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.6 million (down 39.4% YoY) and the FY2025 annual result came in at $29.1 million, up 149.79% from the prior year.
- Cash from Financing Activities fell to $7000.0 in Q1 2026 per NVCT's latest filing, from $166000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $15.5 million in Q1 2025 and troughed at -$578000.0 in Q2 2022.
- A 5-year average of $4.9 million and a median of $1.5 million in 2024 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2023 and 2026: Cash from Financing Activities jumped 2386.33% in 2023, then sank 99.95% in 2026.
- Over 5 years, Cash from Financing Activities stood at -$131000.0 in 2022, then surged by 800.0% to $917000.0 in 2023, then soared by 317.56% to $3.8 million in 2024, then sank by 95.66% to $166000.0 in 2025, then tumbled by 95.78% to $7000.0 in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $7000.0, $166000.0, and $13.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Nuvectis Pharma | 506.13 Mn | 506.13 Mn | - | 1.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.56 Mn |
| Jun 30, 2026 | 1.56 Mn |
| Mar 31, 2026 | 7,000.00 |
| Mar 31, 2026 | 7,000.00 |
| Dec 31, 2025 | 166,000.00 |
| Dec 31, 2025 | 166,000.00 |
| Sep 30, 2025 | 13.14 Mn |
| Sep 30, 2025 | 13.14 Mn |
| Jun 30, 2025 | 296,000.00 |
| Jun 30, 2025 | 296,000.00 |
| Mar 31, 2025 | 15.51 Mn |
| Mar 31, 2025 | 15.51 Mn |
| Dec 31, 2024 | 3.83 Mn |
| Dec 31, 2024 | 3.83 Mn |
| Sep 30, 2024 | 1.46 Mn |
| Sep 30, 2024 | 1.46 Mn |
| Jun 30, 2024 | 1.67 Mn |
| Jun 30, 2024 | 1.67 Mn |
| Mar 31, 2024 | 4.70 Mn |
| Mar 31, 2024 | 4.70 Mn |